A 52-year-old woman from Delhi presents to the emergency department with 2 hours of acute substernal chest pain, nausea, and diaphoresis. She has a history of diabetes and hypertension. Vital signs: BP 118/76 mmHg, HR 88/min. 12-lead ECG shows ST elevation of 2.5 mm in leads V1, V2, V3, and V4 with reciprocal ST depression in II, III, and aVF. Troponin I is 2.4 ng/mL (normal <0.04). She is allergic to aspirin (documented urticaria). What is the most appropriate antiplatelet regimen?

Explanation

## Diagnosis: Acute Anterior Wall STEMI with Aspirin Allergy **Key Point:** In aspirin-allergic patients with STEMI, current ACC/AHA and ESC guidelines recommend substituting aspirin with a single potent P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel) — NOT combining two P2Y12 inhibitors simultaneously. **High-Yield:** Dual P2Y12 inhibitor therapy (e.g., ticagrelor + clopidogrel together) is NOT a guideline-recommended strategy. It increases bleeding risk without proven additional benefit and is not supported by any major trial or guideline. ### Antiplatelet Agents in STEMI: Comparison | Agent | Loading Dose | Onset | Potency | Notes | |-------|--------------|-------|---------|-------| | Aspirin | 325 mg | 15–30 min | Standard | First-line; irreversible COX inhibition | | Clopidogrel | 600 mg | 2–6 hours | Moderate | Prodrug; slower onset; acceptable alternative | | Ticagrelor | 180 mg | 30 min | High | Direct-acting; faster onset; preferred in ACS | | Prasugrel | 60 mg (30 mg if <60 kg) | 30 min | High | Direct-acting; potent; avoid if prior stroke/TIA | ### Rationale for Correct Answer (Option C) This patient has: - **Anterior STEMI** (ST elevation in V1–V4 = LAD occlusion) - **Aspirin allergy** (documented urticaria = true hypersensitivity; aspirin is contraindicated) - **Elevated troponin** (confirms acute MI) Management: 1. **Cannot use aspirin** → replace aspirin with a potent P2Y12 inhibitor as monotherapy 2. **Ticagrelor 180 mg loading dose alone** is the most appropriate choice because: - It is a direct-acting, reversible P2Y12 inhibitor with rapid onset (~30 min) - Superior to clopidogrel in ACS outcomes (PLATO trial — Wallentin et al., NEJM 2009) - ACC/AHA 2013/2021 STEMI guidelines and ESC 2023 guidelines endorse ticagrelor (or prasugrel) as the preferred P2Y12 inhibitor in STEMI - In aspirin-allergic patients, ticagrelor monotherapy replaces the aspirin component; a second antiplatelet is not added 3. **Proceed to primary PCI** within 90 minutes of first medical contact 4. **Anticoagulation** with unfractionated heparin or bivalirudin should be initiated ### Why the Other Options Are Wrong - **Option A (Clopidogrel alone):** Acceptable only if ticagrelor/prasugrel are unavailable or contraindicated; clopidogrel is a prodrug with slower, variable onset and is less potent — not the preferred agent when ticagrelor is available. - **Option B (Clopidogrel + Ticagrelor):** Dual P2Y12 inhibitor therapy is NOT guideline-recommended. Combining two P2Y12 inhibitors increases bleeding risk without proven benefit. This is not standard of care per any major guideline (ACC/AHA, ESC). - **Option D (Prasugrel + Clopidogrel):** Similarly, combining two P2Y12 inhibitors is not indicated. Prasugrel alone would be an acceptable alternative to ticagrelor, but not in combination with clopidogrel. **Clinical Pearl:** Aspirin desensitization is possible in true aspirin allergy but is time-consuming and not feasible in the acute STEMI setting. Ticagrelor monotherapy is the immediate, guideline-endorsed solution. (Reference: Harrison's Principles of Internal Medicine, 21e, Ch. 297; ACC/AHA 2021 STEMI Guidelines) **Warning:** Do NOT combine two P2Y12 inhibitors — this is a common distractor in exam questions and is not supported by evidence or guidelines.